Recurrent ovarian cancer
Clinical trials for Recurrent ovarian cancer explained in plain language.
Never miss a new study
Get alerted when new Recurrent ovarian cancer trials appear
Sign up with your email to follow new studies for Recurrent ovarian cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control Not yet recruitingThis study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if t…
Matched conditions: RECURRENT OVARIAN CANCER
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New therapy aims to ease trauma in ovarian cancer patients
Symptom relief Not yet recruitingThis phase III trial tests a therapy called CALM-TF for women with advanced ovarian cancer who experience traumatic stress. 300 participants will either receive 3-6 sessions of this trauma-focused therapy or standard care. Researchers will measure stress, depression, and quality …
Matched conditions: RECURRENT OVARIAN CANCER
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can ultrasound sharpen the surgical map for ovarian cancer near the liver?
Knowledge-focused Not yet recruitingThis study tests whether a standardized ultrasound approach can reliably classify how ovarian cancer involves the liver area before surgery. Researchers will compare ultrasound images with what surgeons actually find during operations, using tissue samples as an extra check when …
Matched conditions: RECURRENT OVARIAN CANCER
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC